RecallDepth

MicroVue CIC-C1q EIA, Model A001. An enzyme immunoassay for the detection of circulating immune complexes in human serum or plasma. The assay uses highly pure, functional human C1q coated in the solid phase to capture immune complexes (CIC). In the first stage, CIC in the diluted patient samples and HAGG in the controls and standards are dispensed into the C1q coated assay wells. After incubation, unbound material is removed in a washing step and a ready to use conjugate (goat anti-human Ig-HRP) is added. After a second incubation, unbound conjugate is washed away. After addition of a substrate and a short incubation interval, the quantity of CIC in the sample (g Eq/ml) can be determined by comparison to a standard curve.

This recall has been terminated (originally issued April 4, 2017).

Company
Diagnostic Hybrids, Inc.
Recall Initiated
April 4, 2017
Terminated
August 28, 2020
Recall Number
Z-1496-2018
Quantity
101 kits
Firm Location
Athens, OH
Official Source
View on FDA website ↗

Reason for Recall

There is a potential for the slope of the standard curve to fail to meet the assay validation requirements for the assay.

Distribution

The products were distributed to the following US states: NY, TX, CO, UT. The products were distributed to the following foreign countries: Switzerland.

Lot / Code Info

Lot 084007

Root Cause

Other

Action Taken

Customers were notified via letter on 4/4/17. Customers were asked to review their current inventory for the specified lot and complete and return the response form. If the product was further distributed, customers were instructed to provide them with the notification letter.

More recalls by Diagnostic Hybrids, Inc.

View all recalls by this company →